HYPERCOAGULABILITY AND ITS ASSOCIATION WITH METABOLIC AND PRO-INFLAMMATORY MARKERS OF CARDIOVASCULAR RISK IN PATIENTS WITH MULTIPLE MYELOMA
(Abstract release date: 05/21/15)
EHA Library. Dzis I. 06/12/15; 102638; PB1861
Disclosure(s): Institute Of Blood Pathology and Transfusion MedicineHematology
Ivan Dzis
Contributions
Contributions
Abstract
Abstract: PB1861
Type: Publication Only
Background
Patients with multiple myeloma (??) have an increased risk of thrombotic complications. The incidence of venous thromboembolism in patients with MM ranges from 3% to 10%. Hypercoagulability is one of prognostic biomarkers of venous and arterial thrombosis.
Aims
To identify associations between blood markers of coagulation activation, systemic inflammation, lipid and protein metabolism in patients with MM to elaorate prognostic markers of thrombotic events.
Methods
Our study involved 22 patients with MM, 14 men and 8 women aged 46-81 years, and a control group of 16 healthy people. Parameters of hemostasis, systemic inflammation, protein and lipid metabolism were studied. In statistics, Mann-Whitney test and Kendall's tau correlation were used. Medians and interquartile intervals were used to describe parametric data.
Results
In the group of patients with MM, markers of hypercoagulability, such as increased levels of fibrin monomer and D-dimer were found in 77.3% of cases. Frequencies of other cardiovascular risk factors were the following: overweight/obesity – 81.8%, hyperuricemia – 45.5%, atherogenic dyslipidemia with higher than optimal levels of low density lipoprotein cholesterol (LDL-Ch) and low levels of high density lipoprotein cholesterol – 68.2%, increased inflammatory markers CRP and IL-6 – 77.3%. There were significantly higher levels of fibrinogen – 5,35 (3,93-6,87) g/L vs 3,80 (3,49-4,40) g/L (p=0,005), fibrin monomer – 6 (4-10) mg/dL vs 3 (3-3,5) mg/dL (p=0,002) and D-dimer – 90,05 (32,9-487,8) ng/mL vs 21,55 (18,96-35,50) ng/mL (p<0,001) in comparison with the control group. Fibrinogen levels correlated positively with body mass index (BMI) (τ=0.63, ?=0.001), levels of total cholesterol (τ=0.44, ?=0.004), LDL-Ch (τ=0.42, ?=0.006), albumin in percentage (τ=0.43, ?=0.007), and correlated negatively with total protein (τ=-0.41, ?=0.01) and M-protein levels (τ=-0.35, ?=0.029). Fibrin monomer levels correlated positively with fibrinogen (τ=0.51, ?=0.001), IL-6 (τ=0.51, ?=0.001), triglycerides levels (τ=0.47, ?=0.002), albumin in percentage (τ=0.38, ?=0.018), and correlated negatively with M-protein (τ=-0.34, ?=0.034) and IgA levels (τ=-0.56, ?=0.034). D-dimer levels correlated positively with triglycerides levels (τ=0.32, ?=0.035). Thus, in myeloma patients, increased BMI, systemic inflammation and atherogenic hyperlipidemia promotes hypercoagulability. Laboratory data of more severe disease stage according to parameters of protein metabolism were associated with less significant features of hypercoagulability.
Summary
Keyword(s): Hypercoagulation, Inflammation, Lipid metabolism, Multiple myeloma
Type: Publication Only
Background
Patients with multiple myeloma (??) have an increased risk of thrombotic complications. The incidence of venous thromboembolism in patients with MM ranges from 3% to 10%. Hypercoagulability is one of prognostic biomarkers of venous and arterial thrombosis.
Aims
To identify associations between blood markers of coagulation activation, systemic inflammation, lipid and protein metabolism in patients with MM to elaorate prognostic markers of thrombotic events.
Methods
Our study involved 22 patients with MM, 14 men and 8 women aged 46-81 years, and a control group of 16 healthy people. Parameters of hemostasis, systemic inflammation, protein and lipid metabolism were studied. In statistics, Mann-Whitney test and Kendall's tau correlation were used. Medians and interquartile intervals were used to describe parametric data.
Results
In the group of patients with MM, markers of hypercoagulability, such as increased levels of fibrin monomer and D-dimer were found in 77.3% of cases. Frequencies of other cardiovascular risk factors were the following: overweight/obesity – 81.8%, hyperuricemia – 45.5%, atherogenic dyslipidemia with higher than optimal levels of low density lipoprotein cholesterol (LDL-Ch) and low levels of high density lipoprotein cholesterol – 68.2%, increased inflammatory markers CRP and IL-6 – 77.3%. There were significantly higher levels of fibrinogen – 5,35 (3,93-6,87) g/L vs 3,80 (3,49-4,40) g/L (p=0,005), fibrin monomer – 6 (4-10) mg/dL vs 3 (3-3,5) mg/dL (p=0,002) and D-dimer – 90,05 (32,9-487,8) ng/mL vs 21,55 (18,96-35,50) ng/mL (p<0,001) in comparison with the control group. Fibrinogen levels correlated positively with body mass index (BMI) (τ=0.63, ?=0.001), levels of total cholesterol (τ=0.44, ?=0.004), LDL-Ch (τ=0.42, ?=0.006), albumin in percentage (τ=0.43, ?=0.007), and correlated negatively with total protein (τ=-0.41, ?=0.01) and M-protein levels (τ=-0.35, ?=0.029). Fibrin monomer levels correlated positively with fibrinogen (τ=0.51, ?=0.001), IL-6 (τ=0.51, ?=0.001), triglycerides levels (τ=0.47, ?=0.002), albumin in percentage (τ=0.38, ?=0.018), and correlated negatively with M-protein (τ=-0.34, ?=0.034) and IgA levels (τ=-0.56, ?=0.034). D-dimer levels correlated positively with triglycerides levels (τ=0.32, ?=0.035). Thus, in myeloma patients, increased BMI, systemic inflammation and atherogenic hyperlipidemia promotes hypercoagulability. Laboratory data of more severe disease stage according to parameters of protein metabolism were associated with less significant features of hypercoagulability.
Summary
To predict the risk of arterial and venous thrombosis in patients with MM it is advisable to determine BMI, blood levels of fibrinogen, fibrin monomer, D-dimer, CRP, IL-6, and lipid fractions.
Keyword(s): Hypercoagulation, Inflammation, Lipid metabolism, Multiple myeloma
Abstract: PB1861
Type: Publication Only
Background
Patients with multiple myeloma (??) have an increased risk of thrombotic complications. The incidence of venous thromboembolism in patients with MM ranges from 3% to 10%. Hypercoagulability is one of prognostic biomarkers of venous and arterial thrombosis.
Aims
To identify associations between blood markers of coagulation activation, systemic inflammation, lipid and protein metabolism in patients with MM to elaorate prognostic markers of thrombotic events.
Methods
Our study involved 22 patients with MM, 14 men and 8 women aged 46-81 years, and a control group of 16 healthy people. Parameters of hemostasis, systemic inflammation, protein and lipid metabolism were studied. In statistics, Mann-Whitney test and Kendall's tau correlation were used. Medians and interquartile intervals were used to describe parametric data.
Results
In the group of patients with MM, markers of hypercoagulability, such as increased levels of fibrin monomer and D-dimer were found in 77.3% of cases. Frequencies of other cardiovascular risk factors were the following: overweight/obesity – 81.8%, hyperuricemia – 45.5%, atherogenic dyslipidemia with higher than optimal levels of low density lipoprotein cholesterol (LDL-Ch) and low levels of high density lipoprotein cholesterol – 68.2%, increased inflammatory markers CRP and IL-6 – 77.3%. There were significantly higher levels of fibrinogen – 5,35 (3,93-6,87) g/L vs 3,80 (3,49-4,40) g/L (p=0,005), fibrin monomer – 6 (4-10) mg/dL vs 3 (3-3,5) mg/dL (p=0,002) and D-dimer – 90,05 (32,9-487,8) ng/mL vs 21,55 (18,96-35,50) ng/mL (p<0,001) in comparison with the control group. Fibrinogen levels correlated positively with body mass index (BMI) (τ=0.63, ?=0.001), levels of total cholesterol (τ=0.44, ?=0.004), LDL-Ch (τ=0.42, ?=0.006), albumin in percentage (τ=0.43, ?=0.007), and correlated negatively with total protein (τ=-0.41, ?=0.01) and M-protein levels (τ=-0.35, ?=0.029). Fibrin monomer levels correlated positively with fibrinogen (τ=0.51, ?=0.001), IL-6 (τ=0.51, ?=0.001), triglycerides levels (τ=0.47, ?=0.002), albumin in percentage (τ=0.38, ?=0.018), and correlated negatively with M-protein (τ=-0.34, ?=0.034) and IgA levels (τ=-0.56, ?=0.034). D-dimer levels correlated positively with triglycerides levels (τ=0.32, ?=0.035). Thus, in myeloma patients, increased BMI, systemic inflammation and atherogenic hyperlipidemia promotes hypercoagulability. Laboratory data of more severe disease stage according to parameters of protein metabolism were associated with less significant features of hypercoagulability.
Summary
Keyword(s): Hypercoagulation, Inflammation, Lipid metabolism, Multiple myeloma
Type: Publication Only
Background
Patients with multiple myeloma (??) have an increased risk of thrombotic complications. The incidence of venous thromboembolism in patients with MM ranges from 3% to 10%. Hypercoagulability is one of prognostic biomarkers of venous and arterial thrombosis.
Aims
To identify associations between blood markers of coagulation activation, systemic inflammation, lipid and protein metabolism in patients with MM to elaorate prognostic markers of thrombotic events.
Methods
Our study involved 22 patients with MM, 14 men and 8 women aged 46-81 years, and a control group of 16 healthy people. Parameters of hemostasis, systemic inflammation, protein and lipid metabolism were studied. In statistics, Mann-Whitney test and Kendall's tau correlation were used. Medians and interquartile intervals were used to describe parametric data.
Results
In the group of patients with MM, markers of hypercoagulability, such as increased levels of fibrin monomer and D-dimer were found in 77.3% of cases. Frequencies of other cardiovascular risk factors were the following: overweight/obesity – 81.8%, hyperuricemia – 45.5%, atherogenic dyslipidemia with higher than optimal levels of low density lipoprotein cholesterol (LDL-Ch) and low levels of high density lipoprotein cholesterol – 68.2%, increased inflammatory markers CRP and IL-6 – 77.3%. There were significantly higher levels of fibrinogen – 5,35 (3,93-6,87) g/L vs 3,80 (3,49-4,40) g/L (p=0,005), fibrin monomer – 6 (4-10) mg/dL vs 3 (3-3,5) mg/dL (p=0,002) and D-dimer – 90,05 (32,9-487,8) ng/mL vs 21,55 (18,96-35,50) ng/mL (p<0,001) in comparison with the control group. Fibrinogen levels correlated positively with body mass index (BMI) (τ=0.63, ?=0.001), levels of total cholesterol (τ=0.44, ?=0.004), LDL-Ch (τ=0.42, ?=0.006), albumin in percentage (τ=0.43, ?=0.007), and correlated negatively with total protein (τ=-0.41, ?=0.01) and M-protein levels (τ=-0.35, ?=0.029). Fibrin monomer levels correlated positively with fibrinogen (τ=0.51, ?=0.001), IL-6 (τ=0.51, ?=0.001), triglycerides levels (τ=0.47, ?=0.002), albumin in percentage (τ=0.38, ?=0.018), and correlated negatively with M-protein (τ=-0.34, ?=0.034) and IgA levels (τ=-0.56, ?=0.034). D-dimer levels correlated positively with triglycerides levels (τ=0.32, ?=0.035). Thus, in myeloma patients, increased BMI, systemic inflammation and atherogenic hyperlipidemia promotes hypercoagulability. Laboratory data of more severe disease stage according to parameters of protein metabolism were associated with less significant features of hypercoagulability.
Summary
To predict the risk of arterial and venous thrombosis in patients with MM it is advisable to determine BMI, blood levels of fibrinogen, fibrin monomer, D-dimer, CRP, IL-6, and lipid fractions.
Keyword(s): Hypercoagulation, Inflammation, Lipid metabolism, Multiple myeloma
{{ help_message }}
{{filter}}